Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 176,635 |
|
|||||
| News | (1) | ||||||
| Day High | 1.64 | Low High |
|||||
| Day Low | 1.41 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| NextCure Inc | NXTC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.09 | -5.88% | 1.44 | 16:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.53 | 1.41 | 1.64 | 1.44 | 1.53 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 507 | 176,635 | $ 1.50 | $ 264,159 | - | 0.98 - 2.57 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:24:05 | formt | 198 | $ 1.51 | USD |
NextCure Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 39.9M | 27.90M | - | 0 | -62.72M | -2.25 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NextCure News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NXTC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.63 | 1.72 | 1.41 | 1.56 | 81,681 | -0.19 | -11.66% |
| 1 Month | 1.95 | 2.57 | 1.41 | 2.12 | 207,066 | -0.51 | -26.15% |
| 3 Months | 1.17 | 2.57 | 1.16 | 1.76 | 309,412 | 0.27 | 23.08% |
| 6 Months | 1.23 | 2.57 | 0.98 | 1.61 | 194,887 | 0.21 | 17.07% |
| 1 Year | 1.57 | 2.57 | 0.98 | 1.61 | 120,792 | -0.13 | -8.28% |
| 3 Years | 9.62 | 10.23 | 0.98 | 4.50 | 162,146 | -8.18 | -85.03% |
| 5 Years | 15.55 | 109.00 | 0.98 | 16.88 | 238,469 | -14.11 | -90.74% |
NextCure Description
| NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is an immunomedicine against an immunomodulatory receptor called Siglec-15, or S15. |
